Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics.

Simon R.

Expert Opin Med Diagn. 2008 Jun;2(6):721-9. doi: 10.1517/17530059.2.6.721.

PMID:
23495781
2.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
3.

Targeting EGFR in colorectal cancer.

Messersmith WA, Ahnen DJ.

N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/NEJMe0806778. No abstract available.

PMID:
18946069
4.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

5.

The use of genomics in clinical trial design.

Simon R.

Clin Cancer Res. 2008 Oct 1;14(19):5984-93. doi: 10.1158/1078-0432.CCR-07-4531. Review.

6.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.

7.

The taxane limbo: how low can we go?

Hudis C, Dang C.

J Natl Cancer Inst. 2008 Jun 4;100(11):761-3. doi: 10.1093/jnci/djn155. Epub 2008 May 27. Review. No abstract available.

8.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

9.

Letting the genome out of the bottle--will we get our wish?

Hunter DJ, Khoury MJ, Drazen JM.

N Engl J Med. 2008 Jan 10;358(2):105-7. doi: 10.1056/NEJMp0708162. No abstract available.

10.

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. Review.

PMID:
17954709
11.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

12.

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

Jiang W, Freidlin B, Simon R.

J Natl Cancer Inst. 2007 Jul 4;99(13):1036-43. Epub 2007 Jun 27.

13.

Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity.

Goldstein NS, Hunter S, Forbes S, Odish E, Tehrani M.

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):203-7.

PMID:
17525635
14.

Recommendations for improved standardization of immunohistochemistry.

Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG; Members of Ad-Hoc Committee On Immunohistochemistry Standardization.

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):124-33.

PMID:
17525622
15.

Development and clinical indications of cetuximab.

Labianca R, La Verde N, Garassino MC.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6. Review.

PMID:
17520580
16.

TAILORx: trial assigning individualized options for treatment (Rx).

Sparano JA.

Clin Breast Cancer. 2006 Oct;7(4):347-50. No abstract available.

PMID:
17092406
17.

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO.

J Clin Oncol. 2006 Nov 20;24(33):5313-27. Epub 2006 Oct 23.

18.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.

Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

PMID:
17019432
19.
20.

New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK.

Hayes DF, Ethier S, Lippman ME.

Breast Cancer Res Treat. 2006 Nov;100(2):237-8. Epub 2006 Jun 14. No abstract available.

PMID:
16773436
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk